scholarly journals Plasma Amyloid-β in Relation to Antibodies Against Herpes Simplex Virus, Cytomegalovirus, and Chlamydophila pneumoniae

2021 ◽  
pp. 1-7
Author(s):  
Karin Lopatko Lindman ◽  
Bodil Weidung ◽  
Jan Olsson ◽  
Maria Josefsson ◽  
Anders Johansson ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Antimicrobial Properties ◽  
Amyloid Β ◽  
Chlamydophila Pneumoniae ◽  
Immunosorbent Assays ◽  
Simplex Virus ◽  
Ig G ◽  
Xmap Technology

Background: Amyloid-β (Aβ), the key constituent of Alzheimer’s disease (AD) plaques, has antimicrobial properties. Objective: To investigate the association between plasma Aβ and antibodies against the AD-related pathogens herpes simplex virus (HSV), cytomegalovirus (CMV), and C. pneumoniae. Methods: Plasma from 339 AD cases, obtained on average 9.4 years (±4.00) before diagnosis, and their matched controls were analyzed for Aβ40 and Aβ42 concentrations with Luminex xMAP technology and INNOBIA plasma Aβ-form assays. Enzyme-linked immunosorbent assays were utilized for analyses of anti-HSV immunoglobulin (Ig) G, anti-HSV1 IgG, anti-HSV2 IgG, anti-CMV IgG, and anti-C. pneumoniae IgG. Follow-up samples were available for 163 of the cases. Results: Presence and levels of anti-HSV1 IgG, anti-HSV2 IgG, anti-CMV IgG, and anti-C. pneumoniae IgG did not correlate with concentrations of Aβ42 or Aβ40 in cases or controls. Conclusion: Levels of plasma Aβ were not associated with antibodies against different AD-related Spathogens.

Safety and tolerability of intratumorally administered OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A phase I dose escalation clinical study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 3139-3139
Author(s):  
Jing Huang ◽  
Bo Zhang ◽  
Jialin Tang ◽  
Qing Chang ◽  
Rui Zhang ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Oncolytic Viruses ◽  
Potential Clinical Benefit ◽  
Oncolytic Herpes Simplex Virus ◽  
Systemic Treatments ◽  
Simplex Virus

3139 Background: There have been limited reports concerning treatment outcomes of oncolytic viruses in solid tumors other than melanoma. OH2 is a genetically engineered oncolytic herpes simplex virus type 2 designed to selectively amplify in tumor cells and express GM-CSF to enhance tumor-specific immune responses. Methods: We conducted an open-label, single-center, phase 1 study. Eligible pts were 18-75 years of age; had histologically confirmed advanced solid tumor; had progressed after standard systemic treatments. Pts were required to have tumor(s) deemed safe to inject, with a longest diameter of at least 0.5cm. Other eligibility criteria included measurable lesion as per RECIST v1.1; ECOGPS score of 0-1 and adequate organ functions. A 3+3 dose-escalation strategy was used in the study and 3 dose levels (106, 107 and 108 CCID50/mL) of OH2 were assessed. OH2 was administered intratumorally every 3 weeks for the first cycle and every 2 weeks.Treatment may continue afterwards in ptswith potential clinical benefit at the discretion of the investigators. The primary objective was the safety and tolerability of OH2 injection as defined by the dose limiting toxicities (DLTs) within the first 3 weeks of therapy, and the maximum tolerated dose (MTD). Secondary objectives included efficacy and immunogenicity of OH2. Results: 11 pts were enrolled between April 17, 2019 and November 4, 2019. The median follow-up duration was 8.36 months (95%CI: 5.64-11.08). OH2 was well-tolerated as no DLTs were reported and no MTD reached. Before the end of the DLT assessment period,1 pt withdrew consent, and 1 pt died of arrhythmia unrelated to OH2, with negative OH2 DNA copies in serum, urine and saliva samples. Most treatment-related adverse events (TRAEs) observed were of grade 1-2, except that 1 pt in the 108 CCID50/mL group developed grade 3 fever. The most common TRAEs were fever (n =5) and blood bilirubin level increase (n = 4). There were no grade 4 or 5 TRAEs. One pt(rectal cancer) had PR and 2 (appendix cancer and ovarian cancer) had SD as per RECIST v1.1. One patient (esophageal cancer) achieved iPR as per iRECIST criteria. The duration of follow-up for the 2 responders were 9.70 months and 8.36 months, respectively, and both had ongoing responses. Notably, regression of a non-injected lesion was observed in 1 patient. Conclusions: OH2 had a favorable safety profile with no DLTs and MTD. The dose expansion study in selected tumor types is currently underway. Clinical trial information: NCT03866525 .

scholarly journals Comparison of a Multiplexed Herpes Simplex Virus Type-Specific Immunoglobulin G Serology Assay to Immunoblot, Western Blot, and Enzyme-Linked Immunosorbent Assays

2008 ◽  
Vol 16 (1) ◽  
pp. 55-60 ◽  
Author(s):  
Thomas B. Martins ◽  
Ryan J. Welch ◽  
Harry R. Hill ◽  
Christine M. Litwin
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Western Blot ◽  
Immunoglobulin G ◽  
Multiplex Assay ◽  
Specific Alternative ◽  
Specific Antigens ◽  
Immunosorbent Assays ◽  
Simplex Virus ◽  
Hsv 1

ABSTRACT The human herpes simplex virus (HSV) is highly pathogenic, with infections caused by two distinct antigenic types, HSV-1 and HSV-2. Differentiation of antibodies to these specific antigens can provide useful information for the diagnosis of subclinical or undiagnosed HSV-2 infections, as well as for reducing the risk of maternal transfer of HSV to the neonate. In this study, a multiplex assay capable of concurrent detection of HSV-1 and -2 immunoglobulin G (IgG) antibodies was compared to immunoblot, Western blot, and enzyme-linked immunosorbent assays. Agreement of the multiplex assay was 95% or greater (n = 332) for both HSV-1 and -2 compared to the three assays. Sensitivities for HSV-1 ranged from 94.9 to 97.9%, with specificities of 93 to 97%. For HSV-2, the sensitivity and specificity ranges were 92.6 to 98.9% and 98.3 to 98.7%, respectively. Our studies show that the multiplexed microsphere-based assay offers a sensitive and specific alternative method for the detection HSV-1 and -2 type-specific antibodies. Advantages of the multiplex assay include multiple results per assay, the inclusion of internal controls for each specimen, and higher throughput of results.

scholarly journals ДЕЯКІ ПОКАЗНИКИ ГУМОРАЛЬНОГО ІМУНІТЕТУ ТА СТАН МІКРОБІОЦЕНОЗУ РЕПРОДУКТИВНИХ ШЛЯХІВ ЖІНОК-ВНУТРІШНЬО ПЕРЕМІЩЕНИХ ОСІБ ІЗ ЗАГРОЗОЮ ПЕРЕРИВАННЯ ВАГІТНОСТІ

2021 ◽  
pp. 56-63
Author(s):  
A. V. Boychuk ◽  
I. Yu. Romanenko
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Epstein Barr ◽  
Simplex Virus ◽  
Ig G

Мета дослідження – вивчити стан мікробіоценозу репродуктивних шляхів та показники гуморального імунітету жінок-внутрішньо переміщених осіб (ВПО) із загрозою переривання вагітності (ЗПВ) для вдосконалення лікувально-профілактичних заходів та профілактики акушерських і перинатальних ускладнень. Матеріали та методи. Обстежено 51 вагітну в I і II триместрах, які перебували на стаціонарному лікуванні з приводу ЗПВ у лікарнях Луганської області й мали статус ВПО (група I). Контрольну групу (група II) склали 64 вагітних із необтяженим анамнезом та фізіологічним перебігом вагітності аналогічного гестаційного терміну й місця проживання. Проведено комплексне клініко-лабораторне обстеження, бактеріоскопічне обстеження вмісту піхви і цервікального каналу, визначення імуноглобулінів класу Ig G до Herpes simplex virus I–II типів (HSV), Cytomegalovirus (CMV) та Epstein–Barr virus (EBV). Результати дослідження та їх обговорення. Кількість випадків неспецифічного вагініту і бактеріального вагінозу вірогідно частіше (р<0,05) реєстрували у жінок групи I (23,53 і 9,38 % та 19,61 і 6,25 % відповідно), нормоценоз достовірно частіше (р<0,05) виявлено в групі II (82,81 і 52,94 % відповідно). Анти-Ig G HSV виявлено у 90,32 % жінок групи I та у 95,24 % –  групи II, анти-IgG CMV – в 80,65 і 85,71 %, анти-IgG до капсидного антигену EBV VCA – в 74,19 і 71,43 % випадків відповідно, антитіла до ранніх антигенів EBV (анти-IgG EBV ЕА) у всіх вагітних були відсутні. Поєднання анти-IgG HSV + анти-IgG CMV відмічено в 70,97 і 71,43 %, серопозитивність анти-IgG HSV + анти-IgG CMV + анти-IgG EBV VCA – в 48,39 і 52,38 % випадках відповідно. Висновки. Розповсюдженість порушень мікробіоценозу серед вагітних-ВПО із ЗПВ у I та II триместрі становить 47,06 %. Антенатальна оцінка серологічного статусу та стану вагінального біоценозу на початку вагітності незалежно від клінічної симптоматики дозволить індивідуалізувати підхід до ведення і своєчасно розробити в разі потреби коригувальні заходи, які будуть сприяти благополучному завершенню вагітності і впливати на здоровʼя матері та її потомства.

scholarly journals Anti-NMDAR Encephalitis Following Herpes Simplex Virus Encephalitis: 2 Cases From Portugal

2019 ◽  
Vol 10 (2) ◽  
pp. 133-138
Author(s):  
Ana Brás ◽  
Ana André ◽  
Laura Sá ◽  
João Carvalho ◽  
Anabela Matos ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Specific Treatment ◽  
Autoimmune Encephalitis ◽  
Herpes Simplex Virus Encephalitis ◽  
Virus Encephalitis ◽  
Nmdar Encephalitis ◽  
Initial Improvement ◽  
Simplex Virus

Herpes simplex virus encephalitis (HSVE) usually presents as a monophasic disease. Symptomatic HSVE relapsing with seizures, encephalopathy, or involuntary movements associated with anti- N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis have been recently reported. We report 2 cases of adult post-HSVE anti-NMDAR encephalitis from Portugal. Two female patients aged 50 years and 30 years were diagnosed with herpes simplex virus type 2 and type 1 encephalitis, respectively. After the initial improvement with specific treatment and despite virologic negativization, both patients suffered clinical, electroencephalographic, and imaging deterioration. The autoimmune encephalitis hypothesis was confirmed with the demonstration of anti-NMDAR antibodies in both cerebrospinal fluid and serum. Both responded to human immunoglobulin and methylprednisolone, with progressive gain of autonomy along the follow-up period. Thymectomy for thymic hyperplasia diagnosed during follow-up was performed in 1 patient. Although being rare, post-HSVE anti-NMDAR encephalitis should be considered in all cases of symptomatic recrudescence after HSVE, since adequate immune-modulating treatment improves the outcome. The role of thyme hyperplasia in autoimmune encephalitis pathogenesis needs better understanding.

Sign in / Sign up

Export Citation Format

Share Document